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KEY PO INT S
l Autosomal recessive
loss-of-function
mutations in G6b-B
(MPIG6B) cause
congenital
macrothrombocytopenia
with focal
myelofibrosis.
l G6b-B has orthologous
physiological functions
in human and mice
regulating
megakaryocyte and
platelet production and
function.
Unlike primary myelofibrosis (PMF) in adults, myelofibrosis in children is rare. Congenital
(inherited) forms of myelofibrosis (cMF) have been described, but the underlying genetic
mechanisms remain elusive. Herewe describe 4 families with autosomal recessive inherited
macrothrombocytopenia with focal myelofibrosis due to germ line loss-of-function mu-
tations in the megakaryocyte-specific immunoreceptor tyrosine-based inhibitory motif
(ITIM)-containing receptor G6b-B (G6b, C6orf25, or MPIG6B). Patients presented with a
mild-to-moderate bleeding diathesis, macrothrombocytopenia, anemia, leukocytosis and
atypical megakaryocytes associated with a distinctive, focal, perimegakaryocytic pattern
of bone marrow fibrosis. In addition to identifying the responsible gene, the description of
G6b-B as the mutated protein potentially implicates aberrant G6b-B megakaryocytic signaling
and activation in the pathogenesis of myelofibrosis. Targeted insertion of human G6b in mice
rescued the knockout phenotype and a copy number effect of human G6b-B expression was
observed.Homozygous knockinmice expressed25%of humanG6b-B andexhibited amarginal
reduction in platelet count and mild alterations in platelet function; these phenotypes were
more severe in heterozygous mice that expressed only 12% of human G6b-B. This study
establishes G6b-B as a critical regulator of platelet homeostasis in humans and mice. In addition, the humanizedG6bmouse
will provide an invaluable tool for further investigating the physiological functions of human G6b-B as well as testing the
efficacy of drugs targeting this receptor. (Blood. 2018;132(13):1399-1412)
Introduction
Myelofibrosis in children is rare, and, in children, is most com-
monly seen in association with acute megakaryoblastic leu-
kemia.1 Other causes include acute lymphoblastic leukemia
(ALL),2 Hodgkin lymphoma,3 severe vitamin D or C deficiency,4-6
renal osteodystrophy,7 osteopetrosis, hyperparathyroidism,8
autoimmunity,9-11 and tuberculosis.12 The clinical, histologic and
molecular features of pediatric myelofibrosis differ from primary
myelofibrosis (PMF) in adults, which is typically due to somatic
gain-of-function mutations in tyrosine kinase (TK) signaling
pathways, including JAK2 V617F (50%), MPL W515K/L (5% to
10%) or CALR (35%)13,14; TK mutations are not typically present in
pediatric myelofibrosis, particularly not in young children.1,15,16
Children with myelofibrosis have a heterogeneous phenotype
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with variable outcomes. Some patients have spontaneous
resolution,17,18 while others have an aggressive clinical course
with progressive, sometimes fatal disease cured only by hema-
topoietic stem cell transplantation (HSCT).15,19-21
Congenital or inherited forms of myelofibrosis (cMF) are ex-
ceedingly rare with fewer than 50 cases reported.15,18-26 Many
cases occur in consanguineous families,15,19,25 suggesting that
cMF can be inherited as a autosomal recessive Mendelian trait.
Genetic lesions have been identified in only a small minority of
cases. In some, concurrent single lineage cytopenias have been
described. For example, homozygous germ line mutations in
VPS45 cause neutropenia, neutrophil dysfunction, bone marrow
(BM) fibrosis, progressive marrow failure and organomegaly.27,28
In some patients, fibrosis coexists with an intrinsic platelet dis-
order, such as gray platelet syndrome (GPS) to gain-of-function
mutations in the Growth Factor Inhibitor 1B (GFI1B) gene29 or
biallelic mutations in neurobeachin-like 2 (NBEAL2).30-32 These
phenotypes are quite distinct from most patients with cMF.
Here we describe the clinical phenotype, distinctive histological
features andbiallelic loss-of-functionmutations in themegakaryocyte-
specific immunoreceptor tyrosine-based inhibitor motif (ITIM)-
containing receptor G6b-B (C6orf25 or MPIG6B, referred to as
G6b) in four families with a clinically distinctive form of cMF as-
sociated with macrothrombocytopenia and focal myelofibrosis
(cMTFM). These phenotypes closely resemble those reported in
G6b knockout (KO) and loss-of-function mice (Geer et al).33,34 A
humanized G6b transgenic knockin (KI) mouse model establishes
that human and mouse G6b-B perform orthologous functions.
Mice homozygous for humanG6b (G6bhu/hu) exhibit a mild platelet
disorder attributed to reduced human G6b-B expression. Re-
duced G6b-B expression in G6bhu/hu and heterozygous (G6bhu/2)
mice also revealed novel regulatory roles of G6b-B with respect
to immunoreceptor tyrosine-based activation motif (ITAM) and
hemi-ITAM receptor signaling.
Materials and methods
Patients
Families 1-3 consented to the Pediatric Myelodysplastic Syndrome
and Bone Marrow Failure Registry (Boston Children’s Hospital, Pro-
tocol #10-02-0057). Family 4 was consented to the Biomedical Re-
search Centres/Units Inherited Diseases Genetic Evaluation-Bleeding
and Platelet Disorders (BRIDGE-BPD) study (UK REC10/H0304/6).
All studies were conducted according to the Declaration of Helsinki.
Hematological characterization and
sample preparation
Complete blood counts (CBC) and BMaspirates and biopsies were
obtained on all clinically affected individuals; CBCs were obtained
on other family members. Whole blood or BM mononuclear cell
DNAwas extracted using theQiagen Puregene Blood Kit (Qiagen,
Germantown, MD). BM aspirate and biopsy histology were pre-
pared using standard clinical procedures. Images were obtained
with an Olympus BX43 microscope and DP25 digital camera and
acquired with the Olympus CellSens Entry Imaging Software.
Flow cytometry, immunohistochemistry,
and immunoblotting
Flow cytometry was performed on an BD Accuri C6 flow
cytometer using methods and antibodies described in the
supplemental Methods (available on the Blood Web site). Im-
munohistochemical (IHC) staining for CD61 was done on the
Bouin-fixed, paraffin-embedded tissue sections using the Ven-
tana Discovery XT automated platform. A similar, custom au-
tomated IHC method was developed using a monoclonal
antibody directed against the N-terminal ectodomain of G6b-B.33
western blotting and immunoprecipitations were performed as
previously described.35
Linkage and sequencing analysis
Affymetrix 6.0 SNP genotyping (QuintilesIMS, Research Triangle
Park, NC)was performedonmembers of the index family (family 1)
and analyzed using a custom platform (Variant Explorer, K.S.-A.
and K.M., unpublished). Whole exome sequencing (WES) was
performed in patients and immediate family members of family 1
using the Illumina TrueSeq enrichment protocol. Families 2 and 3
were sequenced using the Agilent SureSelect exome capture
enrichment protocol. Sequencing was performed on an Illumina
Hisequation 2000/2500 with 100 bp paired-end sequencing with
an average depth of 40-200x (Macrogen, Rockville, MD). FASTq
sequences were processed and analyzed using the WuXi/
NextCode platform (Cambridge, MA). For individual 4-II-3,
DNA library preparation, sequencing, variant calling and variant
filtering were performed as described previously.36 Confirmatory
Sanger sequencing was carried out on all patients and available
family members as described in the supplemental Methods.
Mouse models
Humanized G6b KI mice were generated as outlined in supple-
mental Figure 1 and supplementarymaterial (Taconic Biosciences,
Cologne, Germany).G6b constitutiveKO (G6b2/2) mousemodels
were generated as previously described.33 All mice were on a
C57BL/6 background and procedures were undertaken with UK
Home Office approval, in accordance with the Animals (Scientific
Procedures) Act of 1986. Detailed descriptions of all other
methods can be found in supplemental Methods.
Results
Clinical and pathological characteristics
We studied four consanguineous Arab families presenting with
macrothrombocytopenia, anemia and myelofibrosis. Family 1,
from the United Arab Emirates (UAE), had three affected male
siblings born to first cousin parents. Affected individuals
(Figure 1A; Table 1, 1-III-1, 1-III-5, and 1-III-6) had macro-
thrombocytopenia with variably reduced platelet granularity,
and microcytic anemia. BM studies revealed clusters of atypical
megakaryocytes with reticulin fibrosis that was most pronounced
in proximity to the megakaryocytes. Affected children had mild
to moderate bleeding symptoms and required frequent platelet
and occasional red cell transfusions; each affecte individual
shared a homozygous human leukocyte antigen (HLA) haplotype
and had congenital adrenal hyperplasia (CAH) due to 21-
hydroxylase (CYP21A2) deficiency. The children had three ap-
parently unaffected cousins born to siblings of their parents. One
female cousin had CAH and shared the same homozygous HLA
type as her affected cousins (Figure 1A; Table 1, 1-III-9,). She was
not thrombocytopenic and had only rare large platelets on her
peripheral blood smear (Figure 2C). While being evaluated as a
transplant donor for her cousins, she underwent multiple BM
studies, the first of which showed several lymphoid aggregates
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with associated reticulin, but normal megakaryocytes. Follow-up
BM studies (Figure 2F,I) were normal. Given the lack of a sibling,
unrelated or cord blooddonor, persistent transfusion dependency
and lack of response to immunomodulatory agents, patients
1-III-5 and 1-III-6 underwent successful matched related HSCTs
with 1-III-9 serving as the donor. Both patients engrafted and are
doing well following HSCT. The proband in this family, 1-III-1, was
transplanted using a haploidentical approach from his mother,
and eventually succumbed to transplant-related complications.15
Family 2 (Figure 1) is from Saudi Arabia. The proband (2-II-6),
whose parents are first cousins, had transient thrombocytopenia
at birth. Thrombocytopenia recurred at 6-months of life and was
associated with severe microcytic anemia unresponsive to iron
therapy. BM studies performed elsewhere at age 2-years were
reported to be normal. Severe thrombocytopenia and anemia
persisted despite several courses of intravenous immunoglob-
ulin and steroids. A BM at age 3-years showed a hypercellular
marrow with increased lymphocytes, and clustering of atypical
megakaryocytes with focal reticulin fibrosis. The patient’s older
brother (2-II-5) was found to be an HLA identical match, but was
ineligible as a donor due to moderate macrothrombocytopenia.
BM studies are not available for this individual, though he is
presumed to be clinically affected. Given the lack of a suitable
donor and their mild phenotype requiring only occasional
platelet transfusions, both children continue to be monitored.
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Figure 1. cMTFM is due to mutations in G6b-B (G6b). (A) Family pedigrees. Black arrows point to the probands in each family. Double line indicates a consanguineous
relationship. Ages are provided at the time of the initial evaluation of the youngest affected individual in the family. (B) Ideograms showing cMTFM linkage region, the G6b
(MPIG6B) locus and patient mutations. (C) Expression of p.Gly157Arg mutant in DT40 cells leads to protein instability and (D-E) reduced expression on the surface of the cell
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Figure 2. Pathology of cMTFM.Wright-Giemsa–stained peripheral blood smears from (A) a normal control, (B) patient 3-II-4 and (C) the clinically unaffected, genotypicallyG6b-
mutated individual 1-III-9 (original magnification31000). Note the large, hypogranular platelets (arrow) and RBC anisocytosis in 3-II-4 and the rare giant platelet in 1-III-9 (arrow).
Serial histologic sections of a bonemarrow biopsies from (D,G,J,M) a normal control individual, (E,H,K,N) 3-II-4, and (F,I,L,O) 1-III-9 stained with (D-F) H&E (original magnification
3400), (G-I) Reticulin (original magnification3600), (J-L) the megakaryocytic marker CD61 (original magnification3400), and (M-O) G6b-B (original magnification3400). Atypical
megakaryocytes present in stellate clusters associatedwith increased reticulin staining are characteristic of cMTMF. Staining for G6b-B is entirely negative in themegakaryocytes
and platelets from 3-II-4 and 1-III-9.
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The proband in family 3 (Figure 1A, 3-II-4) is the daughter of first
cousin consanguineous parents from the UAE. She presented at
15-months of age with leukocytosis, severe microcytic anemia
and macrothrombocytopenia. Her clinical features were strik-
ingly similar to the affected children in family 1. Her BM showed a
mildly hypercellular marrow for her age with a relative myeloid
hyperplasia and clusters of atypical megakaryocytes with asso-
ciated reticulin fibrosis. Although family 1 and family 3 are not
known to be related, 3-II-4 also has CAH and shares the same
homozygous HLA type andCYP21A2mutation as family 1. She is
currently being followed without therapeutic intervention. JAK2,
MPL, and CALR mutation analysis was negative in patients from
families 1-3 (Table 1).
The fourth family included an affected male and female sibling
pair with macrothrombocytopenia, increased BM megakaryo-
cytes, and grade II BM myelofibrosis (Figure 1A, 4-II-2, 4-II-3).
These children and an unaffected brother were born to first
cousins of Arab descent. The affected boy (4-II-2) had a more
severe phenotype, including anemia with Howell-Jolly bodies,
elevated fetal hemoglobin, dyserythropoiesis and dysmega-
karyopoiesis. Platelet surface expression of GPIba, aIIb, a2 and
GPIV were all unaltered, and there was a minor reduction in
aggregation to ADP (data not shown).
A detailed description of each case is included in the supple-
mental Data: clinical case descriptions.
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Figure 3. Expression ofG6b isoforms in humanizedmousemodel. (A)WT, G6b1/hu,G6bhu/hu, human andG6b2/2 washed platelet lysates (43 108/mL), were resolved by SDS-
PAGE and custom antibodies used to detect mouse G6b-B (mG6b-B), human G6b-B (hG6b-B ), and hG6b-A. Expression was quantified and normalized to (i,ii) WT or (iii,iv)
human lysates, to show relevant expression levels in the mouse models. (B) Quantification of glycosylated and unglycosylated human G6b-A and -B, data normalized
to show percentage of total expression. (C) hG6b-B was immunoprecipitated (IP) from basal and collagen-activated G6bhu/hu and human washed platelet lysates (4 3 108/mL).
Co-IP of Shp1 and Shp2 was investigated by (i) SDS-PAGE before (ii) quantification and normalization to hG6b-B levels. Quantification was completed using Licor Odyssey
system. All data represented as mean 6 SEM (n 5 3-4). ***P , .001.
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Linkage, mutational and protein
expression analyses
We performed Affymetrix SNP 6.0 genotyping on peripheral
blood DNA from 10 individuals from family 1 and assessed
shared regions of homozygosity by descent in 1-III-5 and 1-III-6;
1-III-9 was regarded as having an ambiguous phenotype. The
major histocompatibility locus (MHC) on chromosome 6p, which,
although not statistically significant, showed the strongest linkage
(LOD 5 2.01; Figure 1B). We focused on this region, because
affected individuals in family 1 and 3 had an identical homozygous
HLA type and congenital adrenal hyperplasia (CAH) due to the
identicalCYP21A2mutation (Table 1). Furthermore, both affected
individuals in family 2 had a different, but homozygous, HLA
haplotype; the CYP21A2 and HLA loci are located at 6p21.33 and
6p21.32-6p22.1, respectively (Figure 1B).
WeperformedWESon nuclear families 1-3, and on individual 4-II-3
and interrogated the results for genes in which unambiguously
affectedmembers of each family carried a homozygous rare variant
(allele frequency ,0.005) within the candidate disease interval
predicted to be functionally deleterious. The only gene meeting
these criteria was themegakaryocyte and platelet-specific receptor
G6b (MPIG6B, C6orf25, referred to as G6b-B or G6b).
G6b-B is a transmembrane receptor expressed on the surface of
platelets andmegakaryocytes.33,37-39 G6b-B has one extracellular
immunoglobulin-like domain, a single transmembrane domain
and an immunoreceptor tyrosine-based inhibitory motif (ITIM)
and immunoreceptor tyrosine-based switch motif (ITSM) in its
cytoplasmic tail. Tyrosine phosphorylation of the ITIM and ITSM
provides a docking site for the SRC homology 2 (SH2) domain-
containing tyrosine phosphatases SHP1 (PTPN6) and SHP2
(PTPN11), which mediate downstream signaling.40,41 Murine KO
and loss-of-function models of G6b result in a phenotype very
similar to the patients, including macrothrombocytopenia, ab-
normal platelet function and the perimegakaryocytic pattern of
bone marrow fibrosis present in patients (Geer et al).33,34 BM-
derived mouse G6b-B-deficient megakaryocytes develop and
proliferate normally in vitro, but failed to form highly branched
proplatelets, suggesting that G6b-B regulates proplatelet for-
mation, correlating with reduced platelet production.33
Families 1 and 3 shared the same variant, a two base pair dupli-
cation bridging a splice donor site, NM_138272.2 c.61_6111dup
(p.?), and family 2 had a unique homozygous frameshift mutation,
c.149dup (p.Ala52GlyfsX128; Figure 1B). These variants segre-
gated with the phenotype in families 2 and 3; however, in family 1,
individual 1-III-9, who had served as the HSCT donor for her
cousins, genotyped as a homozygous mutant, despite having no
overt clinical features of the disease other than rare giant platelets
(Figure 2C). In family 4, we found a novel apparently homozygous
missense variant c.469G.A (p.Gly157Arg; Figure 1B). The variant
was also homozygous in the affected brother.
Residues 143-163 encode the predicted transmembrane do-
main of G6b-B, and substituting a glycine with arginine would
likely destabilize insertion of the receptor into the membrane.
Expression of the p.Gly157Arg mutant protein was tested using
transiently transfected DT40 cells. Introduction of the mutation
caused a significant reduction in total G6b-B protein expression
(Figure 1C), and surface expression was reduced by 84% by flow
cytometry (Figure 1D-E). A comparable reduction in expression
was also observed in transiently transfected Chinese hamster
ovary (CHO) cell line (data not shown). These data suggest that
this rare missense variant is functionally significant.
To further validate G6b variants as disease-causing, we evalu-
ated G6b-B expression in BM biopsy specimens from affected
Table 2. Peripheral blood counts of indicated mouse genotypes
Hematological
parameters WT, n5 36 G6b1/hu, n 5 37 G6bhu/hu, n 5 37 G6bhu/2, n 5 31 G6b2/2, n 5 37 l P
Platelets, 109/L 1118 6 209 1127 6 219 884 6 214*** 795 6 187*** 206 6 86*** 0.2 2 3 10272
Mean platelet volume, fL 5.8 6 0.2 5.8 6 0.2 6.1 6 0.5*** 6.2 6 0.4*** 7.8 6 0.4*** 22 2 3 10265
Plateletcrit, % 0.4 6 0.1 0.4 6 0.1 0.3 6 0.1 0.3 6 0.1 0.1 6 0 — —
Red blood cells, 1012/L 11.1 6 0.7 10.5 6 0.7 10.7 6 0.8 10.4 6 0.6 10.0 6 0.6 — —
Hematocrit, % 33.6 6 2.4 32.7 6 1.8 33.1 6 2.5 34.1 6 1.9 31.8 6 1.7 — —
White blood cells, 109/L 7.5 6 3.6 8.6 6 2.3 7.4 6 2.6 10.1 6 6.1 13.1 6 6.8*** 0.5 8 3 1027
Lymphocytes, 109/L 6.2 6 2.7 7.4 6 2.0 6.9 6 2.2 7.8 6 3.7 11.8 6 4.9*** 0.5 3 3 10211
Monocytes, 109/L 0.5 6 0.4 0.3 6 0.2 0.5 6 0.2 0.3 6 0.3 0.5 6 0.4 — —
Neutrophils, 109/L 0.8 6 0.4 0.9 6 0.4 0.7 6 0.3 1.2 6 0.8 1.7 6 1.1 — —
Eosinophils, 109/L 0.1 6 0.2 0 6 0 0 6 0 0 6 0.1 0 6 0 — —
Basophils, 109/L 0.1 6 0.3 0 6 0 0.1 6 0.2 0 6 0.1 0.1 6 0.1 — —
All values expressed as mean 6 SD.
—, indicates that no statistical analysis was performed; l, the coefficient for the power transformation to minimize heteroscedasticity and nonnormality; P, the result of a 1-way ANOVA on
transformed data.
***P , .001 compared with WT with the Dunnett post hoc test.
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patients and control samples by IHC using a monoclonal anti-
body specific to the ectodomain. G6b-B was strongly and se-
lectively expressed in megakaryocytes and platelets of control
BM samples, but completely absent in megakaryocytes and
platelets of the genotypically affected individuals from families
1-3 (Figure 2J-O). BM biopsy samples were not available for
patient 4-II-2 or 4-II-3 with the p.Gly157Arg mutation. Thus, in
combination with the complementary phenotype observed in
G6b2/2 mice,33 the thrombocytopenia and BM myelofibrosis
found in these patients is almost certainly due to reduced or
absent expression of G6b-B.
Expression of human G6b-B in G6bhu/hu mice
To confirm that human and mouse G6b-B are orthologous, we
generated a humanized G6bmouse model in which mouse G6b
was replacedwith its human counterpart (supplemental Figure 1;
supplemental Methods). Mice were born at expectedMendelian
frequencies from heterozygous (G6b1/hu) breeding pairs (supple-
mental Table 1), andG6bhu/humicewere healthy, fertile and survived
.25 weeks without any overt developmental or growth anomalies.
Expression of human and mouse G6b-B was verified by flow
cytometry (supplemental Figure 2) andwestern blotting (Figure 3A).
Expression of the humanG6b-A splice isoform, which lacks the ITIM
and ITSM, was also demonstrated using an isoform-specific anti-
body (Figure 3Ai,iv). Both human isoforms were only expressed at
25% of normal human platelet levels. The ratio of glycosylated (32
kDa) to unglycosylated (28 kDa) human G6b-B and -A was reduced
from 3:2 in human platelets to 2:3 in G6bhu/hu platelets (Figure 3B).
The ability of human G6b-B to bind mouse Shp1 and Shp2 was
also investigated inG6bhu/hu platelets (Figure 3C). Similar amounts
of human andmouse Shp1 and Shp2 co-immunoprecipitated (co-
IP’d) with human G6b-B from human andG6bhu/hu platelets under
resting conditions (Figure 3Cii). However, less Shp1 co-IP’d with
human G6b-B from G6bhu/hu platelets compared with human
platelets following collagen-stimulation, most likely reflecting
differences in expression levels of Shp1 and Shp2 in human and
mouse platelets (supplemental Figure 3).42,43 In contrast, com-
parable amounts of Shp2 co-IP’d with human G6b-B from
collagen-stimulated human and G6bhu/hu platelets.
Human G6b-B functionally replaces mouse G6b-B
Reduced human G6b-B expression resulted in an 21% reduction
in platelet count and a marginal increase in platelet volume in
G6bhu/hu mice (Table 2; supplemental Figure 4). In contrast,
complete ablation of G6b resulted in a .80% reduction in
platelet count and .30% increase in platelet volume (Table 2),
demonstrating that human G6b-B rescues the KO phenotype.
Altered blood cell counts in G6b KO mice were independent of
age (supplemental Figure 5). Histological sections of spleens and
femurs also demonstrated that expression of human G6b rescues
the perimegakaryocytic pattern of bone marrow fibrosis previously
identified in G6b KO mice (supplemental Figure 6).33 All other
hematological parameters were normal in G6bhu/hu mice (Table 2).
Blood counts were normal inG6b1/hu andG6b1/2 mice (Table 2).33
Platelet surface levels of GPVI, CLEC-2, a2, aIIb and GPIba were
normal in platelets from G6bhu/hu mice (supplemental Figure 7).
Reduced human G6b-B expression causes minor
alterations in platelet function
G6bhu/hu platelets provide a unique model to investigate the
physiological consequence of reduced human G6b-B levels in
platelets, without altered expression of other receptors identified in
G6b2/2 mice.33 No significant defects were observed in aIIbb3-
mediated adhesion and spreading of G6bhu/hu platelets on
fibrinogen, in the presence or absence of thrombin (supplemental
Figure 8). Consistentwith thesefindings, outside-inaIIbb3 signaling
was comparable betweenWT andG6bhu/hu platelets (supplemental
Figure 9). Bands corresponding to tyrosine phosphorylated mouse
(45 kDa) and human (28-34 kDa doublet) G6b-B were observed in
fibrinogen-adhered WT and G6bhu/hu platelets, respectively. As
G6bhu/hu mice do not express mouse G6b-B (Figure 3), the tyrosine
phosphorylated band at 45 kDa (supplemental Figure 9) is due to
the presence of other co-migrating phosphorylated proteins.
We next investigated (hemi)-ITAM receptor-mediated functional
responses. Unexpectedly, platelet aggregation was marginally
reduced in response to low and intermediate concentrations
(1-10 mg/mL) of the GPVI-specific agonist collagen-related
peptide (CRP) (Figure 4A). In contrast, CLEC-2-mediated
platelet aggregation was marginally increased at 6 mg/mL anti-
CLEC-2 antibody (Figure 4A). Platelet aggregation to thrombin,
collagen, ADP and the TxA2 analog U46619 were normal
(supplemental Figure 10). ATP secretion from dense granules
was normal to all agonists tested (Figure 4A; supplemental
Figure 10), except for aminor increase at an intermediate dose of
collagen. These findings reveal minor alternations in platelet
functional responses due to reduced human G6b-B expression
that are likely of no physiological consequence.
Altered G6bhu/hu platelet function does not affect
thrombus formation or hemostasis
We further investigated G6bhu/hu platelet functional responses
under physiological flow conditions on different thrombogenic
surfaces. Platelet adhesion and thrombus formation were
quantified by flowing anti-coagulated blood over: (1) collagen;
(2) von Willebrand factor-binding protein (vWF-BP) and laminin;
and (3) vWF-BP, laminin and the CLEC-2 agonist rhodocytin, for
3.5 minutes at 1000 s21. Surface area coverage and morpho-
logical scores were used as measures of platelet adhesion and
thrombus formation (supplemental Figure 11). Regression
analysis of a cohort ofWTmice (n5 19) did not indicate that the
21% reduction in platelet counts in G6bhu/hu mice will affect any of
the measured parameters (supplemental Figure 12). The total
surface area covered by G6bhu/hu platelets on collagen was un-
altered compared with WT platelets (Figure 4B). However, multi-
layer thrombus formation and contraction were both significantly
Figure 4. Minor alterations of G6bhu/hu platelet functional responses. (A) Averaged aggregation and ATP release traces for washed platelets (2 3 108/mL) activated with
indicated concentrations of CRP (i) and anti-CLEC-2 antibody (Ab) (ii). Area under the curve (AUC) quantification of (iii) platelet aggregation and (iv) ATP release (n 5 5-6 per
condition, **P , .01 and *P , .05). (B) Heparin-PPACK-fragmin anticoagulated whole blood was flowed over glass coverslips coated with collagen immediately following
collection. (i) Brightfield images were immediately collected, followed by staining with PE-conjugated JON/A, FITC-conjugated P-selectin, and Alexa 647–conjugated Annexin V
and fluorescence imaging. Analysis quantifying (ii-vi) thrombus surface area coverage and morphological scores of adhered platelets, (n5 5-6; ***P, .001; **P, .01) and (vii-ix)
surface area coverage of fluorescently labeled antibodies (n5 5-6; ***P, .001; *P, .05). (C) Total blood loss to body weight ratio of mice following excision of tail tip (n5 12-16;
***P , .001; **P , .01). All data collection and analysis in panels B and C were completed blinded, mean 6 SEM. Scale bar, 10 mm.
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increased, despite a minor reduction in aIIbb3 activation and
normal a-granule release, measured by immunostaining with
JON/A and P-selectin antibodies, respectively (Figure 4B). Altered
thrombusmorphologyofG6bhu/huplatelets ismost likely a reflection
of the increased proportion of phosphatidylserine (PS)-positive
procoagulant platelets,measuredbyAnnexin V staining (Figure 4B).
No difference in adhesion or platelet activation were observed
when anti-coagulated blood from WT and G6bhu/hu mice was flowed
over vWF-BP and laminin, or vWF-BP, laminin and rhodocytin
(supplemental Figure 13). Although some minor alterations in
G6bhu/hu platelet activation were identified using this assay,
expression of human G6b-B rescued the severe defects observed
in G6b2/2 platelets. This rescue is likely due to a combination of
increased platelet counts and normalized platelet reactivity.
Functional defects observed inG6bhu/huplatelets did not culminate
in compromised hemostasis in mice, as assessed using the tail
bleeding assay, whereas G6b2/2 mice bled excessively, as pre-
viously reported (Figure 4C).33
To determine the molecular basis of altered responses to CRP and
anti-CLEC-2 antibody, we investigated tyrosine phosphorylation in
WT andG6bhu/hu platelets. The findings from aggregations studies
were supported by a minor reduction in global tyrosine phos-
phorylation following CRP stimulation (Figure 5A). A trend toward
reduced SFK and Syk activities was identified, as measured by
changes in autophosphorylation of Tyr418 and Tyr519/20 in the
activation loops of SFKs and Syk, respectively, though this did not
reach significance (Figure 5A). SFK-mediated phosphorylation of
the ITAM-containing FcR g-chain, which acts as a docking site for
Syk to propagate signals downstream of GPVI, was also marginally
reduced in CRP-stimulated G6bhu/hu platelets. The opposite was
observed in CLEC-2 activated platelets, in which global tyrosine
phosphorylation, SFK and Syk activation weremarginally increased
in response to antibody-mediated cross-linking and activation of
CLEC-2 (Figure 5B). However, only Syk activation with 10 mg/mL
anti-CLEC-2 antibody was significantly increased.
Further reduction in human G6b-B expression
exacerbates platelet defects
To further investigate the threshold of human G6b-B expression
required to rescue the G6b2/2 phenotype, we generated human
G6b hemizygous mice (G6bhu/2) by crossing G6bhu/hu mice with
G6b2/2mice (Figure 6A).G6bhu/2mice expressedonly 12%of human
G6b-B and -A compared with human platelets, and nomouseG6b-B
(Figure 6A; supplemental Figure 14A, B). These expression levels
produced an even greater reduction in platelet counts (29%) and
a comparable increase in platelet volume (6% to 7%) compared
with G6bhu/hu mice (Table 2). This provides further evidence that
human G6b-B dose dependently regulates platelet production.
Surface receptor expression was normal in G6bhu/2 platelets
compared with WT platelets, except for CLEC-2, which was mar-
ginally reduced by 16% (supplemental Figure 14C). Interestingly,
platelet aggregation was further reduced in response to CRP and
increased in response to antibody-mediated cross-linking of CLEC-2
(Figure 6B). These findings demonstrate differential roles of
G6b-B in regulating ITAM- and hemi-ITAM-containing receptor-
mediated platelet activation at these expression levels. No dif-
ference was observed upon activation of CLEC-2 using the snake
toxin rhodocytin. This likely reflects the tetravalent structure of
rhodocytin that can elicit a more robust CLEC-2 activating signal,
thus abrogating the mild phenotype observed with the biva-
lent anti-CLEC-2 antibody. Thrombin-mediated aggregation of
G6bhu/2 platelets was normal and no significant defects in ATP
secretion was observed for all agonists tested.
Discussion
Here we have described four families with a distinct phenotype
of macrothrombocytopenia, microcytic anemia, variable leuko-
cytosis and histologically characteristic megakaryocytic cluster-
ing, dysplasia and focal reticulin fibrosis in the BM presenting at
young age. We attribute this to homozygous loss-of-function
mutations inG6b, the gene encoding G6b-B, a megakaryocytic/
platelet-specific ITIM-containing receptor. While this work was in
preparation, another consanguineous Arab family with a similar
phenotype was described with a homozygous predicted null
mutation inG6b.26 These data firmly support the conclusion that
recessive loss-of-function mutations in G6b result in the phenotype
that we comprehensively describe and term congenital macro-
thrombocytopenia with cMTFM. All of the clinically affected patients
have a phenotype strikingly similar to a null mutation,33 or mu-
tations that abolish ITIM/ITSM signaling (Geer et al)34 in the murine
ortholog. Concomitantly, we have demonstrated that theG6bKO
phenotype can be rescued upon expression of human G6b.
One apparently clinically unaffected individual, 1-III-9, without
thrombocytopenia or anemia at the time of her evaluation as a
transplant donor, also shares the G6b-B mutation; she did not have
thrombocytopenia, bleeding symptoms, leukocytosis, anemia, or
atypical megakaryocytes associated with fibrosis, but did have rare
large platelets. She did have transient BM lymphoid aggregates that
are unusual for such a young child; these might be indicators of a
primary BM disorder, but could equally be due to her CAH or other
causes. Thus, it is likely that even genotypically similar patientsmight
have varying expressivity or penetrance of the phenotype due to
othermodifying factors, including age, environment, andgenotypes
at other loci. Indeed, for example, patient 2-II-5 came to medical
attention only becauseof hismore severely affected younger sibling,
2-II-6. In addition to modifiers noted above, there are several
possible explanations for the successful HSCT of the two siblings,
1-III-5 and 1-III-6 from their cousin, 1-III-9, who shares the same
homozygous mutant G6b genotype. First, it is conceivable that the
conditioning regimen alters the niche directly, which could impact
the regulation of other components important in the regulation of
megakaryocytic development, proplatelet and platelet formation.
Second, introductionof a newhematopoietic stemcell pool from the
donor into the host with cMF could lead to immunological graft and
host interactions between the stem cell compartment and the niche
that could alter megakaryocytic development.
The cMTFM phenotype underscores the importance of G6b-B
signaling in normal megakaryocyte and platelet biology. Binding
of Shp1 and Shp2 are essential for mediating signal transduced
by G6b-B. A mutant form of G6b-B that uncouples it from Shp1
and Shp2 signaling phenocopies the G6b KO mouse model
(Geer et al),33,34 and a tissue-specific mouse model of combined
Shp1 and Shp2 deficiency recapitulates multiple features ofG6b
KO animals,44 further indicating the essential nature of this
signaling pathway to megakaryocyte function.
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Themajority of reported patients with cMF have undergoneHSCT
as it was felt to be the only curative treatment optio.15 The his-
tological resemblance to PMF in adults, which carries a risk of
evolution to acute myeloid leukemia and a poor prognosis, may
have encouraged providers to offer HSCT out of due caution,
even in the absence of evidence for adverse outcomes when
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Figure 5. Altered tyrosine phosphorylation in response to GPVI and CLEC-2 agonists in G6bhu/hu platelets. Representative blots (n 5 3) of lysates prepared from washed
platelets (4 3 108/mL) activated with indicated concentrations of (Ai) CRP (90 seconds, 10 mM lotrafiban, 10 mM indomethacin, and 2 U/mL apyrase) or (Bi) CLEC-2 Ab
(300 seconds, 10 mM lotrafiban) and probed with the indicated antibodies. (Aii,Bii) Src family kinase (SFK) phosphotyrosine 418 (pTyr418) and (Aiii,Biii) Syk pTyr519/20 were
quantified using ImageJ and normalized to total tubulin and Syk reblots, respectively. WT, blue; G6bhu/hu, red.
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managed conservatively. Indeed, in our series of 7 cases of pa-
tients with G6b mutations, three required HSCT for cytopenias,
one was clinically unaffected, and three have been observed
without ongoing clinical interventions. The identification of a
molecular therapeutic target—Shp1- and Shp2-dependent signal
transduction—now offers the potential to circumvent the G6b-B
(ii) (iii)
Ag
gr
eg
at
io
n 
(A
UC
)
3
CLEC-2 Ab
(g/ml)
3
CRP
(g/ml)
***
***
* *
3
rhodo
(nM)
0
100
200
300
400
500
0.06
thrombin
(U/ml)
AT
P 
re
le
as
e 
(A
UC
) G6bhu/hu
G6bhu/-
WT
0
1
2
3
4
5
3
CLEC-2 Ab
(g/ml)
3
CRP
(g/ml)
3
rhodo
(nM)
0.06
thrombin
(U/ml)
(i) G6bhu/hu G6b-/- G6bhu/-
relative hG6b-B: 25% 0% 12%
(iii)
0
50
100
W
T
G6
b
hu
/-
G6
b
hu
/h
u
hu
m
an
G6
b
-/-
No
rm
al
ise
d 
hu
m
an
G6
b-
B 
ex
pr
es
sio
n 
(%
)
(ii)
mG6b-B43 –
56 –
W
T
G6
b
hu
/-
G6
b
hu
/h
u
hu
ma
n
G6
b
-/-
hG6b-B
tubulin
27 –
hG6b-A
27 –
(i) 3 g/ml CRP
1 min
70%
0%
%
 ag
gr
eg
at
io
n
0
1.6
AT
P 
re
le
as
e
(n
M
)
3 g/ml CLEC-2 Ab
WT 
G6bhu/hu
G6bhu/-
0.06 U/ml thrombin3 nM rhodocytin
A
B
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deficiency in cMTFM and insights into the pathogenesis of other
forms of primary and secondary myelofibrosis.
The humanized G6b mouse provided compelling evidence of the
analogous functions of human and mouse G6b-B. The mild platelet
phenotype, suggests human G6b-B interacts with the same ligands
and signals in a similarmanner tomouseG6b-B. Reducedbindingof
humanG6b-B tomouse Shp1 ismost likely a reflectionof the relative
stoichiometries and binding affinities of Shp1 and Shp2 in mouse
platelets. Mouse platelets contain 6-fold higher levels of Shp2 than
Shp1, whereas human platelets contain 2-foldmore Shp1 than Shp2
(supplemental Figure 3).42,43 In addition, the binding affinity of
tandem SH2 domains of human Shp2 with phosphorylated-G6b-
B-ITIM-ITSM peptide is 100-fold greater than the binding affinity of
tandem SH2 domains of Shp1.45 However, differences in the pro-
portions of human G6b-B bound Shp1 and Shp2 in mouse versus
human platelets are not likely to underlie the platelet defects de-
scribed the humanizedG6bmouse, as mouseG6b-B is predicted to
bind the same ratios of Shp1 and Shp2. Thus, platelet defects are
more likely due to reduced human G6b-B expression.
Despite the significant reduction in human G6b-B in G6bhu/hu and
G6bhu/2 mice, both mouse models exhibited only mild platelet
phenotypes. A large proportion of G6b-B is therefore not essential
for maintenance of platelet homeostasis. MKs from G6b2/2 mice
were previously shown to develop normally in vitro, but with sig-
nificantly diminished proplatelet production capacity.33 Reduced
platelet production in G6bhu/hu and G6bhu/2 mice could therefore
have been as a consequence of aberrant proplatelet formation,
arising from reduced G6b-B expression in MKs. The dose de-
pendent nature of the reduction in platelet counts in these ho-
mozygous and heterozygous mice adds to the growing body of
evidence of the vital role of G6b-B in regulating platelet production.
The reduction in human G6b-B expression was predicted to lead
to an increase in platelet reactivity to collagen. Indeed, thrombus
formation and contraction were significantly increased when
whole blood was flowed over collagen, despite a marginal re-
duction in integrin aIIbb3 activation. This can be explained by an
enhancement in PS exposure and increased procoagulant activity
of G6bhu/hu platelets, which is dependent upon PLCg2-mediated
Ca21 flux and phosphatidylinositol 3-kinase signaling,45 high-
lighting these as potential downstream targets of Shp1 and Shp2.
The dose-dependent reduction in aggregation of G6bhu/hu and
G6bhu/2 platelets to CRP was however, counter-intuitive, sug-
gesting G6b-B may act as both a positive and negative regulator
of GPVI signaling, depending upon expression levels. The can-
didate target of G6b-B-associated Shp1 and Shp2 is Syk tyrosine
kinase that we previously showed is hyper-activated in G6b-
B-deficient platelets.33 Syk contains multiple regulatory tyrosine
phosphorylation sites that Shp1 and Shp2 may differentially de-
phosphorylate, depending upon the expression level of G6b-B,
leading to either positive or negative effects on Syk activity.47
This study establishes that human and mouse G6b-B perform the
same physiological functions, and that deletion and loss-of-function
mutations in G6b-B lead to megakaryocytic and myelofibrotic dis-
orders in both species. Validation of these analogous functions is
essential to progress with exploring the role of G6b-B in various
pathological conditions in humans and as a novel therapeutic drug
target. The humanizedG6b-Bmousemodel describedhereprovides
an invaluable tool for investigating the efficacy and therapeutic
potential of agents targeting human G6b-B in various disease con-
ditions, includingmyeloproliferation andmyelofibrosis, allowing for a
greater understanding of themechanismof action of these therapies.
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47. Mócsai A, Ruland J, Tybulewicz VL. The SYK
tyrosine kinase: a crucial player in diverse bi-
ological functions. Nat Rev Immunol. 2010;
10(6):387-402.
1412 blood® 27 SEPTEMBER 2018 | VOLUME 132, NUMBER 13 HOFMANN et al
D
ow
nloaded from
 http://ashpublications.org/blood/article-pdf/132/13/1399/1467435/blood802769.pdf by U
N
IVER
SITEIT M
AASTR
IC
H
T user on 29 O
ctober 2020
